Catabasis Pharma (CATB) Reports Phase 3 PolarisDMD Clinical Trial for Edasalonexent in Duchenne Muscular Dystrophy Progress Update; Announces Additional Trial Sites Open for Enrollment

January 3, 2019 8:17 AM EST Send to a Friend
Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) today shared an update on clinical trial sites in the United States and recent international ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login